ARCHIVES

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

This article is from The Cancer Letter archive.

Vol. 25 No. 1 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

June 27, 2014

In Brief: NCI’s George Khoury Dies; Panel to Meet June 22 In Pittsburgh; Rosemary Mackey To Leave MDA

May 8, 1987

Schwetz Replaces Koski As HHS Human Research Protections Director

February 7, 2003

Tumor Treating Fields Therapy Increased Three-Year Survival

November 25, 2011

In Brief: MSKCC Launches Molecular Oncology, Genomic Center

May 23, 2014

Cancer Policy: NCAB Chairmen sent Letter To Senator Defending NCI director

April 11, 1997